Head-to-head evidence
CM313 vs SCTC21C
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
CM313
Developed by Keymed Biosciences
NCT04818372 · Phase 1 · status unknown
This is an early, single-arm, open-label safety and dose-finding study with no randomization or comparator group, so it cannot show whether CM313 works better than another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
SCTC21C
Developed by Sinocelltech Group Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07297329 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CM313's landscape · SCTC21C's landscape